Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.570
-0.050 (-3.09%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Galmed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
3.33.924.665.664.13
Upgrade
Research & Development
2.983.571327.2226.08
Upgrade
Operating Expenses
6.287.4917.6532.8830.21
Upgrade
Operating Income
-6.28-7.49-17.65-32.88-30.21
Upgrade
Interest Expense
-0.61----
Upgrade
Interest & Investment Income
0.50.380.30.561.19
Upgrade
Currency Exchange Gain (Loss)
0.04-0.040.04-0.03-0.12
Upgrade
Other Non Operating Income (Expenses)
-0.020.25-0.02-0.04-0.03
Upgrade
EBT Excluding Unusual Items
-6.36-6.9-17.34-32.39-29.17
Upgrade
Gain (Loss) on Sale of Investments
-1.16-0.01-0.53-0.080.4
Upgrade
Pretax Income
-7.52-6.91-17.87-32.47-28.77
Upgrade
Net Income
-7.52-6.91-17.87-32.47-28.77
Upgrade
Net Income to Common
-7.52-6.91-17.87-32.47-28.77
Upgrade
Shares Outstanding (Basic)
10000
Upgrade
Shares Outstanding (Diluted)
10000
Upgrade
Shares Change (YoY)
303.31%65.23%2.22%15.59%0.79%
Upgrade
EPS (Basic)
-8.08-29.95-127.90-237.59-243.35
Upgrade
EPS (Diluted)
-8.08-29.95-127.90-237.59-243.35
Upgrade
Free Cash Flow
-5.88-6.14-18.51-32.9-26.33
Upgrade
Free Cash Flow Per Share
-6.32-26.59-132.48-240.78-222.72
Upgrade
EBITDA
-6.2-7.46-17.62-32.84-30.17
Upgrade
D&A For EBITDA
0.080.030.040.040.04
Upgrade
EBIT
-6.28-7.49-17.65-32.88-30.21
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q